Celixir   Report issue

For profit Phase 2
Founded: Cardiff United States (2009)
Status: Defunct (2023)

Organization Overview

First Clinical Trial
2014
NCT03811145
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Cell Therapy Ltd.

Active Ingredients

Drugs in Phase 2 Trials (2)

immunomodulatory progenitor cells (1 trial)

platelet-rich plasma (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fibrosis (Phase 2)

Tennis Elbow (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2